The subscribers in the Directed Share Issue are, amongst other, STADA Arzneimittel AG, NYIP (Nyenburgh Investment Partners), Swedbank Robur Medica, Belsize Asset Management GmbH and Serendipity Group AB.
Comments from CEO
“We are pleased to welcome STADA and Swedish and international institutional investors to Xbrane. This strengthens the company significantly! With these share issues, our phase III study with Xlucaneis fully financed. STADA’s investment in Xbrane is a powerful sign of a strong belief in Xlucane’scommercial potential. It is very gratifying to lead Xbrane through this phase III trial and continue to work with our portfolio of attractive biosimilars. With this capital raise the Company further targets to move to Nasdaq main market during 2019.”, says Martin Åmark, CEO Xbrane Biopharma